Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cyclobenzaprine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 5/20 | 1.00 |
| ▸ | HRH1 | P35367 | 8/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 7/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 7/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 7/20 | 1.00 |
| ▸ | HTR2B | P41595 | 6/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 6/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 6/20 | 1.00 |
| ▸ | DRD2 | P14416 | 6/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 6/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 6/20 | 1.00 |
| ▸ | DRD3 | P35462 | 6/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 6/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 5/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 5/20 | 1.00 |
| ▸ | HTR1A | P08908 | 5/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 4/20 | 1.00 |
| ▸ | CACNA1B | Q00975 | 3/20 | 1.00 |
| ▸ | MTOR | P42345 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclobenzaprine SCHEMBL29520569 | 1.00 | HRH1 (1.00) | HRH1SLC6A2KCNH2CYP2D6HTR2B | |
| Cyclobenzaprine SCHEMBL7654526 | 1.00 | HRH1 (1.00) | HRH1SLC6A2KCNH2CYP2D6HTR2B | |
| Cyclobenzaprine SCHEMBL29350662 | 0.98 | LMNA (1.00) | HRH1SLC6A2KCNH2CYP2D6HTR2B | |
| Cyclobenzaprine SCHEMBL4964925 | 0.98 | LMNA (1.00) | HRH1SLC6A2KCNH2CYP2D6HTR2B | |
| Cyclobenzaprine SCHEMBL41376 | 0.98 | LMNA (1.00) | HRH1SLC6A2KCNH2CYP2D6HTR2B | |
| Cyclobenzaprine SCHEMBL1649752 | 0.97 | HRH1 (0.93) | HRH1SLC6A2KCNH2CYP2D6HTR2B | |
| Cyclobenzaprine SCHEMBL4606463 | 0.97 | LMNA (0.97) | HRH1SLC6A2KCNH2CYP2D6HTR2B | |
| Cyclobenzaprine SCHEMBL17812696 | 0.92 | HRH1 (0.84) | HRH1SLC6A2KCNH2CYP2D6HTR2B | |
| Cyclobenzaprine SCHEMBL29015268 | 0.91 | HRH1 (0.82) | HRH1SLC6A2KCNH2CYP2D6HTR2B | |
| Cyclobenzaprine SCHEMBL8892591 | 0.91 | HRH1 (0.82) | HRH1SLC6A2KCNH2CYP2D6HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12914 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260108477-A1 | CYCLOBENZAPRINE TREATMENT FOR FIBROMYALGIA | TONIX PHARMA LTD (IE) | 2026-04-23 | — | — | US | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| US-12588828-B2 | Methods and systems for diagnosing and treating fibromyalgia | KATZ ROBERT S (US) | 2026-03-31 | — | — | US | claimed |
| US-12550885-B2 | Red blood cell storage solutions, solution additives, and methods for improving the storage of red blood cells | UNIVERSITY OF CINCINNATI (US) | 2026-02-17 | — | — | US | claimed |
| US-20260027337-A1 | TRANSDERMAL DRUG DELIVERY DEVICES AND METHODS | MORNINGSIDE VENTURE INVESTMENTS LTD (MC) | 2026-01-29 | — | — | US | claimed |
| EP-4683627-A1 | AMELIORATION OF DRUG-DRUG INTERACTIONS | Ontrack Therapeutics Limited (GB) | 2026-01-28 | — | — | EP | claimed |
| US-12515030-B2 | Transdermal drug delivery devices and methods | MORNINGSIDE VENTURE INVESTMENTS LIMITED (MC) | 2026-01-06 | — | — | US | claimed |
| EP-0031561-B1 | A RECTALLY ADMINISTERED SUPPOSITORY COMPRISING A DRUG AND AN ADJUVANT | MERCK & CO. INC. (US) | 1985-04-10 | — | — | EP | claimed |
| EP-0126684-A2 | Drug delivery system utilizing thermosetting gels | MERCK & CO. INC. (US) | 1984-11-28 | — | — | EP | claimed |
| US-4478822-A | Drug delivery system utilizing thermosetting gels | MERCK & CO., INC. (US) | 1984-10-23 | — | — | US | claimed |
| US-4474752-A | DIAMINE MODIFIED POLYOXYETHYLENE-POLYOXYPROPYLENE COPOLYMER | MERCK & CO., INC. (US) | 1984-10-02 | — | — | US | claimed |
| US-4440740-A | α-Keto aldehydes as enhancing agents of gastro-intestinal drug absorption | MERCK & CO., INC. (US) | 1984-04-03 | — | — | US | claimed |
| EP-0083032-A2 | Rectally administrable suppository comprising a drug and an adjuvant | MERCK & CO. INC. (US) | 1983-07-06 | — | — | EP | claimed |
| EP-0069385-A2 | Use of eucalyptol for enhancing skin permeation of bioaffecting agents | MERCK & CO. INC. (US) | 1983-01-12 | — | — | EP | claimed |
| EP-0036145-A1 | An orally administered drug form comprising a polar bioactive agent and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-23 | — | — | EP | claimed |
| EP-0031561-A2 | A rectally administered suppository comprising a drug and an adjuvant | MERCK & CO. INC. (US) | 1981-07-08 | — | — | EP | claimed |
| EP-0009808-A1 | Composition having skeletal muscle relaxant activity | MERCK & CO. INC. (US) | 1980-04-16 | — | — | EP | claimed |